Xiidra | Beye

Compare Dry Eye

6 products »

Home > Ophthalmic Drugs > Dry Eye

Xiidra

Xiidra

Shire

Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).

TOP

Description

Related Products

Details

From Your Peers

In The News

Company

At-a-Glance

Mechanism of Action: Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in dry eye disease is not known.
Dosage: One drop twice daily in each eye (approximately 12 hours apart).

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Lifitegrast

Application

Topical

Status

Prescription

Strength

5%

From Your Peers

Optometrists are equipped to manage dry eye disease with pharmaceutical options such as cyclosporine ophthalmic emulsion 0.05% and lifitegrast ophthalmic solution 5%, and they can address meibomian gland dysfunction with technologies..."

Can’t-Miss Cataract Signs

Blake Williamson, MD, MPH, MS; and Bridgette Connorton, OD

READ ARTICLE »

Dry Eye Cases From a Collaborative Clinic

Dry Eye Cases From a Collaborative Clinic

READ ARTICLE »

Dry Eyes and Increasing Myopia After LASIK

Dry Eyes and Increasing Myopia After LASIK

READ ARTICLE »

Use of artificial tears with surfactants can reduce surface tension and help to increase the lubricity of the lens. However, some patients may need more aggressive treatment regiments such as lifitegrast ophthalmic solution 5%, cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) or punctal plugs."

Troubleshooting Nonwetting Scleral Lenses

Justine L. Siergey, OD, FSLS

READ ARTICLE »

We managed this patient’s significant DED aggressively using warm compresses, LipiFlow thermal pulsation treatment (Johnson & Johnson), loteprednol 0.5% (Lotemax; Bausch + Lomb) four times daily, lifitegrast 5.0% (Xiidra; Shire), and artificial tears. One cannot perform premium cataract surgery using premium lenses without ensuring a premium ocular surface. Paying attention to ocular surface health is the most important thing surgeons can do to improve their outcomes."

Lessons from the PHACO Study

Eric D. Donnenfeld, MD

READ ARTICLE »

If there is significant inflammation of the ocular surface, I add a low-dose topical steroid, loteprednol etabonate ophthalmic suspension 0.5% (»Lotemax; Bausch + Lomb) twice a day, and lifitegrast ophthalmic solution 5%."

Bye Bye, Dry Eye

Gregg J. Berdy, MD, FACS

READ ARTICLE »

Show More

In the News

Takeda Reaches Deal to Buy Shire for $62 Billion »

Eyewire | 05.08.18

ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye »

Eyewire | 05.03.18

Global Dry Eye Treatment Revenues to Grow to $4.9 Billion by 2022 »

Eyewire | 01.09.18

Xiidra Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease »

Eyewire | 01.03.18

Shire Provides Update on Early Xiidra Sales »

Eyewire | 02.17.17

Shire’s Xiidra (Lifitegrast) Is Now Available by Prescription in the United States »

Eyewire | 08.29.16

FDA Approves Shire’s Xiidra (Lifitegrast) for the Signs and Symptoms of Dry Eye Disease »

Eyewire | 07.11.16

Show More

Company Information

Contact the company for additional information, availability, or pricing:

Shire

shire.com

300 Shire Way Lexington

Lexington, MA 02421

Compare Dry Eye »

6 products »

View All Dry Eye »

6 products »

Privacy | Terms & Conditions Ⓒ 2024 Beye, LLC. All rights reserved.

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.